4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA ...

Some guys are getting this promising new weight loss drug on the grey market. Here's what it does and the risks of taking it ...

BridgeBio Pharma, Inc.'s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. Learn ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...

XRP has continued to play a role in global digital payment systems in 2025. Originally designed as a token for cross-border settlement, it is now recognized as a bridge asset that is being adopted by ...

Leaders in Durham are working on a new approach to reduce gun violence. During a joint meeting, elected officials discussed ...

The latest helmets to meet those standards are the Acerbis Airstrike and Airoh Aviator 3 Evo, both of which are off-road lids ...

BOWLING GREEN, Ohio — The final phase of Bowling Green’s South Main Street improvement ... Beginning the week of Nov. 3, ...

Short interest is always a sign of how bearish investors may be on a stock. But it can also serve as a potential sign of a coming short squeeze, especially if the stock in question is rocketing higher ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.